SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRANCHINI, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.674
EU - Europa 2.039
AS - Asia 790
Continente sconosciuto - Info sul continente non disponibili 10
AF - Africa 7
OC - Oceania 7
SA - Sud America 5
Totale 7.532
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.663
IT - Italia 1.044
CN - Cina 514
PL - Polonia 255
DE - Germania 191
UA - Ucraina 190
TR - Turchia 161
GB - Regno Unito 109
SE - Svezia 84
FI - Finlandia 54
BE - Belgio 27
VN - Vietnam 24
HK - Hong Kong 21
IN - India 18
IR - Iran 16
FR - Francia 15
RO - Romania 15
DK - Danimarca 13
NO - Norvegia 12
CA - Canada 10
EU - Europa 10
JP - Giappone 10
NL - Olanda 8
AU - Australia 7
TW - Taiwan 6
BR - Brasile 5
CH - Svizzera 5
CZ - Repubblica Ceca 3
ET - Etiopia 3
GE - Georgia 3
ID - Indonesia 3
IE - Irlanda 3
KR - Corea 3
PK - Pakistan 3
PT - Portogallo 3
RU - Federazione Russa 3
AT - Austria 2
GR - Grecia 2
IL - Israele 2
KE - Kenya 2
MY - Malesia 2
PH - Filippine 2
ES - Italia 1
IQ - Iraq 1
MX - Messico 1
NG - Nigeria 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 7.532
Salva come PNG Salva come JPEG
Città #
Chandler 570
Fairfield 504
Woodbridge 441
Ferrara 308
Ann Arbor 277
Houston 264
Ashburn 263
Warsaw 254
Wilmington 220
Jacksonville 215
Seattle 206
Cambridge 173
New York 125
Izmir 119
Princeton 118
Nanjing 99
Dearborn 88
Milan 77
Beijing 73
Shanghai 70
Bremen 62
San Diego 45
Redwood City 41
Falls Church 35
Nanchang 35
Boardman 34
Shenyang 32
Bologna 28
Los Angeles 25
Rome 25
Dong Ket 23
Brussels 22
Hebei 21
Auburn Hills 20
Jiaxing 20
San Mateo 20
Guangzhou 18
Florence 17
Jinan 17
Kunming 16
Changsha 15
Norwalk 15
Helsinki 14
London 14
Tianjin 14
Washington 12
Zhengzhou 12
Hong Kong 11
Mountain View 11
Hangzhou 10
Ningbo 10
Praia A Mare 10
Monmouth Junction 9
Piemonte 9
Augusta 8
Des Moines 8
Duncan 8
Ferrara di Monte Baldo 8
Hefei 8
Oslo 8
Bari 7
Hounslow 7
Toronto 7
Andover 6
Arona 6
Chicago 6
Leawood 6
Orange 6
Redmond 6
Albissola Marina 5
Catania 5
Haikou 5
Rochester 5
Verona 5
Addison 4
Atlanta 4
Bangalore 4
Cagliari 4
Calderara di Reno 4
Calvisano 4
Castelcovati 4
Civitanova Marche 4
Dallas 4
Fuzhou 4
Gragnano 4
Louvain 4
Quartu Sant'elena 4
Ravenna 4
Sala 4
Terranova 4
Amstelveen 3
Ardabil 3
Copenhagen 3
Genova 3
Guidonia 3
Halesowen 3
Henderson 3
Indiana 3
Ipiranga 3
Livorno 3
Totale 5.410
Salva come PNG Salva come JPEG
Nome #
La sanificazione delle degenze ospedaliere: nuove strategie a supporto della riduzione delle infezioni correlate all’assistenza sanitaria 246
La sanificazione delle degenze ospedaliere: nuove strategie per la riduzione delle infezioni correlate all’assistenza sanitaria 236
Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation 216
The carboxyl-terminal region of coagulation factors: role in biosynthesis and function of FVII and FX 191
Il sistema di sanificazione PCHS Probiotic Cleaning Hygien System: risultati delle indagini sperimentali in vitro e in campo 176
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 158
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 147
PCHS (Probiotic Hygiene Cleaning System) Protocol: reduction of hospital environmental impact with a new and innovative technology for cleaning in Ferrara University Hospital 144
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 142
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 138
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 134
Hard surface biocontrol in hospitals using microbial-based cleaning products 132
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 132
Chronic sleep deprivation markedly reduces coagulation factor VII expression 127
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 120
Reduction of the microbial load on hospital surfaces through probiotic-based cleaning procedures: a new strategy to control nosocomial infections 118
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 116
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 114
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 113
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 113
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 113
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 105
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 99
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 98
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 97
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 97
I probiotici: aspetti generali e valutazioni sulla sicurezza d’impiego 97
null 94
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 94
null 93
F9 genotype and PK hemophilia B international study (GEPKHIS) 93
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 93
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 92
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 88
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 87
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 85
null 84
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 84
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 83
null 73
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 73
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 72
null 71
Improved intracellular processing of protein variants as a personalized therapeutic approach for Haemophilia 69
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 69
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 66
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 66
Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies 64
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 60
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity 60
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 59
Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants 57
null 56
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 56
The carboxyl-terminal region of coagulation serine proteases: A matter of cut and change 56
The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity 55
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 54
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 54
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 52
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 51
A recoded view on the F9 p.Cys178Ter pathogenic mechanism 50
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 50
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 47
Effects of Partial Chronic Sleep Deprivation on the Mouse Blood Coagulation Cascade. 47
null 45
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 45
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 45
null 44
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 44
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 44
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 43
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 43
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 42
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 42
Next generation factor VIIa with enhanced half-life 41
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 40
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 40
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 39
Improved intracellular processing of protein variants as a personalised therapeutic approach for haemophilia 38
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 38
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 38
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 38
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 37
Hemostasis gene expression of the internal jugular and saphenous veins 36
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 35
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 34
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 33
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 32
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 31
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 31
Academic Editor per la rivista PLoS One 30
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 30
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 30
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 29
Caratterizzazione dei determinanti molecolari del processo di soppressione di mutazioni nonsenso mediato da ribosome readthrough 29
Exploring base editing for the correction of nonsense mutations in hemophilia B 28
Associate Editor per la rivista Frontiers in Genetics - sezione Genetic Disorders 28
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 28
Associate Editor per la rivista Frontiers in Pediatrics - sezione Genetic Disorders 26
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 25
Totale 7.577
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.958
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 114
Totale 32.072
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019452 0 0 0 0 0 0 0 0 0 0 150 302
2019/20201.512 240 61 53 185 122 242 151 126 123 125 55 29
2020/20211.400 64 55 53 92 61 100 255 176 82 198 179 85
2021/20221.181 170 139 37 36 82 72 49 48 35 84 74 355
2022/20231.242 132 144 50 174 179 158 77 79 135 11 58 45
2023/2024585 63 67 44 32 54 156 41 62 29 33 4 0
Totale 7.868